Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: SalmonMan who wrote (86736)	3/17/2000 11:56:00 AM
From: KevinMark	Respond to of 108040

GZTR getting some play. They are a tissue repair biotech company. Genzyme Tissue Repair Ticker: GZTR Page 1 of 10 Complete Financials: September 1999 Exchange NASD Earnings Announcement: December 1999* FY END DEC ISSUE DATA (03/10/00) PER SHARE DATA RATIOS Price $ 7.63 EPS (TTM) $ -1.28* P/E (TTM) NM* 52W High $ 11.63 Div. Rate $ 0.00 Yield 0.00 % 52W Low $ 1.31 Book Value $ -0.06 Price/Book NM Shrs Out 25.53 Mil Cash $ 0.57 ROE (TTM) NM% Float 19.90 Mil Rev (TTM) $ 0.85 ROA (TTM) -122.79*% Mon. Vol 17.50 Mil Curr. Ratio 2.50 Beta 1.40 LT Dbt/Eqty NM BRIEF: Genzyme Tissue Repair develops products that will augment or positively modify naturally occurring biological processes involved in tissue repair. For the nine months ended 9/30/99, revenues increased 16% to $14.4M. Net loss decreased 23% to $24.1M. Revenues reflect higher sales of Carticel (R) chondrocytes and Epicel (TM) skin grafts due to patients treated, surgeons trained and insurance approvals. Lower loss reflects reduction in labor and mfg. expenses. PRELIMINARY: For the 3months ended 12/31/1999, revenues were 6,032; after tax earnings were -5,894.